Cargando…
Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors
Advanced endometrial cancer continues to have a poor prognosis, due to limited treatment options, which may be further adversely impacted by obesity. Endometrial cancer stem cells have been reported to drive metastasis, chemotherapy resistance and disease relapse, but have yet to be fully characteri...
Autores principales: | Kitson, Sarah J., Rosser, Matthew, Fischer, Deborah P., Marshall, Kay M., Clarke, Robert B., Crosbie, Emma J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562824/ https://www.ncbi.nlm.nih.gov/pubmed/31083574 http://dx.doi.org/10.3390/cancers11050653 |
Ejemplares similares
-
Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin
por: Sivalingam, Vanitha N., et al.
Publicado: (2019) -
Measuring the biological effect of presurgical metformin treatment in endometrial cancer
por: Sivalingam, V N, et al.
Publicado: (2016) -
Optimization of Window Study Endpoints in Endometrial Cancer
por: Kitson, Sarah J., et al.
Publicado: (2019) -
Metformin Inhibits Expression and Secretion of PEDF in Adipocyte and Hepatocyte via Promoting AMPK Phosphorylation
por: Yang, Shumin, et al.
Publicado: (2013) -
High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer
por: Kitson, Sarah J., et al.
Publicado: (2018)